File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: The role of urotensin II in the metabolic syndrome
  • Basic View
  • Metadata View
  • XML View
TitleThe role of urotensin II in the metabolic syndrome
 
AuthorsOng, KL1
Wong, LYF1
Cheung, BMY1
 
KeywordsDiabetes
Hypertension
Inflammation
Metabolic syndrome
Urotensin II
Vasoactive peptide
 
Issue Date2008
 
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/peptides
 
CitationPeptides, 2008, v. 29 n. 5, p. 859-867 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.peptides.2007.06.003
 
AbstractUrotensin II is a potent vasoconstrictive peptide that mediates both endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. Its plasma level correlates positively with body weight and is raised in diabetes, renal failure, hypertension, and other cardiovascular diseases including congestive heart failure and carotid atherosclerosis. It can inhibit glucose-induced insulin secretion, and genetic variants in urotensin II gene are associated with insulin resistance and type 2 diabetes. Urotensin II also affects lipid metabolism in fish and food intake in mice. Recent studies have also demonstrated a role of urotensin II in inflammation and endothelial dysfunction. These findings suggest a close relationship between urotensin II and at least some components of the metabolic syndrome, including hypertension, insulin resistance, hyperglycemia, and inflammation. © 2007 Elsevier Inc. All rights reserved.
 
ISSN0196-9781
2013 Impact Factor: 2.614
2013 SCImago Journal Rankings: 0.971
 
DOIhttp://dx.doi.org/10.1016/j.peptides.2007.06.003
 
ISI Accession Number IDWOS:000256007400027
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorOng, KL
 
dc.contributor.authorWong, LYF
 
dc.contributor.authorCheung, BMY
 
dc.date.accessioned2010-10-31T11:03:27Z
 
dc.date.available2010-10-31T11:03:27Z
 
dc.date.issued2008
 
dc.description.abstractUrotensin II is a potent vasoconstrictive peptide that mediates both endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. Its plasma level correlates positively with body weight and is raised in diabetes, renal failure, hypertension, and other cardiovascular diseases including congestive heart failure and carotid atherosclerosis. It can inhibit glucose-induced insulin secretion, and genetic variants in urotensin II gene are associated with insulin resistance and type 2 diabetes. Urotensin II also affects lipid metabolism in fish and food intake in mice. Recent studies have also demonstrated a role of urotensin II in inflammation and endothelial dysfunction. These findings suggest a close relationship between urotensin II and at least some components of the metabolic syndrome, including hypertension, insulin resistance, hyperglycemia, and inflammation. © 2007 Elsevier Inc. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationPeptides, 2008, v. 29 n. 5, p. 859-867 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.peptides.2007.06.003
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.peptides.2007.06.003
 
dc.identifier.epage867
 
dc.identifier.hkuros180156
 
dc.identifier.isiWOS:000256007400027
 
dc.identifier.issn0196-9781
2013 Impact Factor: 2.614
2013 SCImago Journal Rankings: 0.971
 
dc.identifier.issue5
 
dc.identifier.openurl
 
dc.identifier.pmid17610998
 
dc.identifier.scopuseid_2-s2.0-42149115655
 
dc.identifier.spage859
 
dc.identifier.urihttp://hdl.handle.net/10722/124955
 
dc.identifier.volume29
 
dc.languageeng
 
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/peptides
 
dc.publisher.placeUnited States
 
dc.relation.ispartofPeptides
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAnimals
 
dc.subject.meshCardiovascular Diseases - metabolism
 
dc.subject.meshHumans
 
dc.subject.meshMetabolic Syndrome X - metabolism - physiopathology
 
dc.subject.meshUrotensins - genetics - metabolism
 
dc.subjectDiabetes
 
dc.subjectHypertension
 
dc.subjectInflammation
 
dc.subjectMetabolic syndrome
 
dc.subjectUrotensin II
 
dc.subjectVasoactive peptide
 
dc.titleThe role of urotensin II in the metabolic syndrome
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ong, KL</contributor.author>
<contributor.author>Wong, LYF</contributor.author>
<contributor.author>Cheung, BMY</contributor.author>
<date.accessioned>2010-10-31T11:03:27Z</date.accessioned>
<date.available>2010-10-31T11:03:27Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Peptides, 2008, v. 29 n. 5, p. 859-867</identifier.citation>
<identifier.issn>0196-9781</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/124955</identifier.uri>
<description.abstract>Urotensin II is a potent vasoconstrictive peptide that mediates both endothelium-independent vasoconstriction and endothelium-dependent vasodilatation. Its plasma level correlates positively with body weight and is raised in diabetes, renal failure, hypertension, and other cardiovascular diseases including congestive heart failure and carotid atherosclerosis. It can inhibit glucose-induced insulin secretion, and genetic variants in urotensin II gene are associated with insulin resistance and type 2 diabetes. Urotensin II also affects lipid metabolism in fish and food intake in mice. Recent studies have also demonstrated a role of urotensin II in inflammation and endothelial dysfunction. These findings suggest a close relationship between urotensin II and at least some components of the metabolic syndrome, including hypertension, insulin resistance, hyperglycemia, and inflammation. &#169; 2007 Elsevier Inc. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier Inc. The Journal&apos;s web site is located at http://www.elsevier.com/locate/peptides</publisher>
<relation.ispartof>Peptides</relation.ispartof>
<subject>Diabetes</subject>
<subject>Hypertension</subject>
<subject>Inflammation</subject>
<subject>Metabolic syndrome</subject>
<subject>Urotensin II</subject>
<subject>Vasoactive peptide</subject>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Cardiovascular Diseases - metabolism</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Metabolic Syndrome X - metabolism - physiopathology</subject.mesh>
<subject.mesh>Urotensins - genetics - metabolism</subject.mesh>
<title>The role of urotensin II in the metabolic syndrome</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0196-9781&amp;volume=29&amp;issue=5&amp;spage=859&amp;epage=867&amp;date=2008&amp;atitle=The+role+of+urotensin+II+in+the+metabolic+syndrome</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.peptides.2007.06.003</identifier.doi>
<identifier.pmid>17610998</identifier.pmid>
<identifier.scopus>eid_2-s2.0-42149115655</identifier.scopus>
<identifier.hkuros>180156</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-42149115655&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>29</identifier.volume>
<identifier.issue>5</identifier.issue>
<identifier.spage>859</identifier.spage>
<identifier.epage>867</identifier.epage>
<identifier.isi>WOS:000256007400027</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong